Bankrupt Savient Gets OK For $120M Sale To Crealta
A Delaware bankruptcy judge on Friday blessed drug developer Savient Pharmaceuticals Inc.'s sale to Crealta Pharmaceuticals LLC for $120.4 million, more than twice the price initially established by the debtor's stalking...To view the full article, register now.
Already a subscriber? Click here to view full article